Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Effectiveness of physical therapy treatment in addition to usual podiatry management of plantar heel pain: a randomized clinical trial
McClinton SM, Heiderscheit BC, McPoil TG, Flynn TW
BMC Musculoskeletal Disorders 2019 Dec 28;20(620):Epub
clinical trial
8/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: Yes; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: Yes; Intention-to-treat analysis: Yes; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

BACKGROUND: Many patients will seek care from a podiatrist for plantar heel pain (PHP), while few of these patients will also be seen by a physical therapist. Physical therapists can provide treatment that is not a part of routine podiatric care for PHP and may provide additional improvement. Therefore, the purpose of this study was to examine the effects of interdisciplinary care for PHP that incorporated physical therapy treatment after initiating podiatric treatment. METHODS: Eligible individuals with PHP that presented to a podiatrist were randomized to receive usual podiatric care (uPOD) or usual podiatric care plus physical therapy treatment (uPOD+PT). The primary outcome was change in foot and ankle ability measure (FAAM) at 6-months. Secondary outcomes included change in numeric pain rating scale (NPRS), patient-reported success, and 6-week and 1-year endpoints. Patient-reported success was defined as the top two global rating of change scale rankings. Primary analysis was intention-to-treat (ITT) using analysis by covariance adjusted to baseline scores, and a secondary per-protocol (PP) analysis was performed analyzing only those who completed treatment. RESULTS: Ninety-five individuals participated and were included in the ITT analysis, and 79 were included in the PP analysis. For the primary outcome of FAAM change from baseline to 6-months, both groups improved significantly (uPOD+PT 26.8 (95% CI 21.6 to 31.9); uPOD 20 (15.6 to 24.4), but there was no between-group difference (4.3 (-1 to 9.6)). For secondary outcomes, the uPOD+PT group demonstrated greater improvement in NPRS at 6 weeks (0.9 (0.3 to 1.4)) and 1 year (1.5 (0.6 to 2.5)) in the ITT analysis. In the PP analysis, the uPOD+PT group demonstrated greater improvement in FAAM at 6 months (7.7 (2.1 to 13.3)) and 1 year (5.5 (0.1 to 10.8)), NPRS at 6 weeks (0.9 (0.2 to 1.6)), 6 months (1.3 (0.6 to 2.1)) and 1 year (1.3 (0.6 to 2.1)), and in patient-reported success (relative risk (95% CI)) at 6 weeks (2.8 (1.1 to 7.1)), 6 months (1.5 (1.1 to 2.1)), and 1 year (1.5 (1.1 to 1.9)). CONCLUSIONS: There was no significant benefit of uPOD+PT in the primary outcome of FAAM change at 6 months. Secondary outcomes and PP analysis indicated additional benefit of uPOD+PT, mostly observed in individuals who completed treatment. TRIAL REGISTRATION: Prospectively registered May 24, 2013 at www.ClinicalTrials.gov (NCT01865734).

Full text (sometimes free) may be available at these link(s):      help